Cancer Epidemiology Overview

Principles

Definition

Cancer epidemiology is the branch of epidemiology concerned with the study of the distribution and determinants of cancer incidence, prevalence, and mortality in human populations. This field employs systematic methods to identify risk factors, understand the etiology of various cancers, and evaluate the effectiveness of interventions, thereby providing essential evidence for public health strategies aimed at cancer prevention and control.

Ontological type

Key Risk Factors

Prevention Strategies

Study Designs

Key developments

Key Figures

Population-Based Etiology era

Richard Peto [1], a leading cancer epidemiologist, was affiliated with Harvard University [2] and the University of Oxford [3] during the Population-Based Etiology era. His 1981 paper The Causes of Cancer: Quantitative Estimates of Avoidable Risks of Cancer in the United States Today [4] quantified avoidable cancer risks using population-based methods and linked exposures to cancer burden. This work solidified Richard Peto [1]'s role in establishing quantitative risk assessment as a core tool for etiologic surveillance in this era. By turning exposure data into tangible avoidable-cancer estimates, the study helped guide early preventive policy and the emergence of standardized population-based tracking practices.

Risk and Molecular Integration era

David Sidransky [1] is a leading cancer researcher whose work in this era is associated with Johns Hopkins University [3] and Baylor College of Medicine [4]. His key contributions include advancing microsatellite instability (MSI) as a biomarker for cancer detection and familial predisposition, as reflected by the 1998 workshop on international criteria for MSI in colorectal cancer [7], which helped standardize molecular assays and improve etiologic inference in risk-based screening. Stephen N. Thibodeau [2] conducted influential work at Rockefeller University [5] and the University of California, San Diego [6] during this era. His key contributions centered on establishing MSI as a robust biomarker for cancer predisposition and refining genetic epidemiology methods through biomarker validation and study design, with the 1998 MSI criteria workshop [7] illustrating the era's shift toward credible molecular risk assessment.

Standardized Global Burden era

Freddie Bray [1], associated with Albert Einstein College of Medicine [3] and Heidelberg University [4], contributed to the Standardized Global Burden era by advancing harmonized cancer burden estimation. Bray [1] helped establish standardized global cancer estimates through GLOBOCAN 2012 [6], GLOBOCAN 2008 [7], and GLOBOCAN 2018 [8], providing sources, methods and major patterns that enable cross-national comparisons and policy planning in this era. Jacques Ferlay [2], affiliated with Royal Australian and New Zealand College of Radiologists [5], has been active in this era. Ferlay [2] co-authored the same GLOBOCAN 2012 [6], GLOBOCAN 2008 [7], and GLOBOCAN 2018 [8] papers, helping to shape harmonized metrics and transparent estimation frameworks that underpin cancer surveillance, resource allocation, and guideline development in this era.